Scientech Research LLC Invests $738,000 in Structure Therapeutics Inc. (NASDAQ:GPCR)

Scientech Research LLC purchased a new stake in Structure Therapeutics Inc. (NASDAQ:GPCR) during the 2nd quarter, HoldingsChannel.com reports. The fund purchased 18,803 shares of the company’s stock, valued at approximately $738,000.

A number of other hedge funds have also added to or reduced their stakes in GPCR. Wellington Management Group LLP raised its stake in shares of Structure Therapeutics by 404.0% in the fourth quarter. Wellington Management Group LLP now owns 4,372,326 shares of the company’s stock worth $178,216,000 after purchasing an additional 3,504,747 shares during the last quarter. Avoro Capital Advisors LLC raised its position in Structure Therapeutics by 133.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company’s stock valued at $95,107,000 after buying an additional 1,333,333 shares during the last quarter. RA Capital Management L.P. lifted its stake in Structure Therapeutics by 210.2% during the 1st quarter. RA Capital Management L.P. now owns 1,510,362 shares of the company’s stock valued at $64,734,000 after acquiring an additional 1,023,530 shares in the last quarter. Capital International Investors purchased a new position in Structure Therapeutics during the 4th quarter worth $34,647,000. Finally, Capital Research Global Investors grew its stake in shares of Structure Therapeutics by 182.3% in the 4th quarter. Capital Research Global Investors now owns 973,535 shares of the company’s stock worth $39,681,000 after acquiring an additional 628,687 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Trading Up 0.5 %

Structure Therapeutics stock opened at $41.75 on Friday. The business’s 50 day simple moving average is $38.14 and its 200 day simple moving average is $39.78. Structure Therapeutics Inc. has a 12 month low of $26.61 and a 12 month high of $75.02. The company has a market cap of $1.95 billion, a price-to-earnings ratio of -54.22 and a beta of -3.52.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. As a group, equities research analysts forecast that Structure Therapeutics Inc. will post -0.86 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a research report on Monday, September 23rd. JMP Securities dropped their target price on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a research report on Friday, August 9th. Morgan Stanley initiated coverage on Structure Therapeutics in a report on Monday, September 23rd. They issued an “overweight” rating and a $118.00 target price for the company. Finally, BMO Capital Markets lifted their price target on Structure Therapeutics from $83.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday, June 7th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $88.33.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.